文献速递肝病

美国肝硬化危重患者肝移植后生存率的改善

Improvement in Survival After Transplantation for Critically Ill Patients With Cirrhosis in the United States.
PubMed 文献 · Am J Gastroenterol · 2024-07-05

该研究基于美国器官共享网络登记数据库,纳入2005至2020年接受单纯肝移植的成人患者,分析了肝硬化危重患者肝移植的流行病学与结局。结果显示危重患者比例从2005-2008年的4.3%升至2017-2020年的7.9%,1年生存率从72.5%升至89.5%,与非危重患者的生存差距从16.7个百分点缩小至4.6个百分点但仍持续存在。

要点

  • 肝硬化危重患者肝移植比例从2005-2008年的4.3%升至2017-2020年的7.9%。
  • 危重患者肝移植后1年生存率从72.5%升至89.5%,绝对提高17%。
  • 危重与非危重患者1年生存差距从16.7个百分点缩小至4.6个百分点但仍存在。

核心结论

  • 肝硬化危重患者肝移植的绝对数量和相对比例随时间增加,肝移植后1年生存率也提高。
  • 该组患者与非危重肝硬化患者之间的生存差距缩小但仍持续存在。
  • 作者认为,在确保与非危重患者生存差距尽可能小的前提下,谨慎选择危重肝移植候选者可能是合理的。

研究设计与样本

  • 研究为基于美国器官共享网络登记数据库的分析,纳入2005年至2020年间接受单纯肝移植的成人患者。
  • 危重肝硬化定义为肝移植时在重症监护室且具备以下至少1项特征:III/IV级肝性脑病、机械通气、透析、使用血管加压药。
  • 共纳入85,594例肝移植受者,其中5,827例(6.8%)在肝移植时被归类为肝硬化危重患者。

主要发现

  • 危重肝移植受者数量和百分比在研究期间增加:2005-2008年为819例(4.3%),2017-2020年为2,067例(7.9%),P < 0.001。
  • 肝移植后1年生存率绝对提高17%:2005-2008年为72.5%,2017-2020年为89.5%,P < 0.001。
  • 危重与非危重肝硬化患者肝移植后1年生存差距缩小:2005-2008年为16.7个百分点,2017-2020年为4.6个百分点。
  • 肝移植年份与较低的肝移植后1年死亡率独立相关(风险比0.92,95%置信区间0.91-0.93,P < 0.001)。

临床怎么用

  • 作者认为,在确保与非危重患者生存差距尽可能小的前提下,谨慎选择危重肝移植候选者可能是合理的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is considerable debate over the indication of liver transplantation (LT) for critically ill patients with cirrhosis, in part due to their potentially poor post-LT prognosis. We analyzed the epidemiology and outcome of LT for critically ill patients with cirrhosis over 4 time periods of 4 years. METHODS: We included adult patients who underwent liver transplant alone between 2005 and 2020 using the United Network for Organ Sharing registry database. We defined critically ill patients with cirrhosis as being in the intensive care unit with 1 or more of the following characteristics at the time of LT: (i) grade III/IV hepatic encephalopathy, (ii) mechanical ventilation, (iii) dialysis, and (iv) vasopressors. RESULTS: A total of 85,594 LT recipients were included, 5,827 (6.8%) of whom were classified as being critically ill with cirrhosis at the time of LT. The number and percentage of critically ill LT recipients with cirrhosis increased over the study period: 819 (4.3%) in 2005-2008 vs 2,067 (7.9%) in 2017-2020, P < 0.001. There was a 17% absolute increase in 1-year survival after LT: 72.5% in 2005-2008 vs 89.5% in 2017-2020, P < 0.001. The 1-year post-LT survival gap between critically ill and noncritically ill patients with cirrhosis narrowed over the study period: 16.7 percentage points in 2005-2008 vs 4.6 percentage points in 2017-2020. The year of LT was independently associated with lower 1-year post-LT mortality (hazard ratio 0.92, 95% confidence interval 0.91-0.93, P < 0.001). DISCUSSION: The absolute number and relative percentage of LT recipients who were critically ill increased over time, as did 1-year post-LT survival. Meanwhile, the gap in survival between this group of patients and noncritically ill patients with cirrhosis decreased but persisted. Cautious access to selected LT candidates who are critically ill may be warranted, provided the gap in survival with noncritically ill patients remains as small as possible.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Artzner T, Goldberg DS, Sundaram V, et al. Improvement in Survival After Transplantation for Critically Ill Patients With Cirrhosis in the United States. Am J Gastroenterol. 2024. PMID: 38976367. doi:10.14309/ajg.0000000000002944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。